Previous close | 63.77 |
Open | 63.86 |
Bid | 61.34 x 200 |
Ask | 61.69 x 100 |
Day's range | 61.28 - 64.51 |
52-week range | 44.27 - 70.81 |
Volume | |
Avg. volume | 160,026 |
Market cap | 1.288B |
Beta (5Y monthly) | 0.81 |
PE ratio (TTM) | 38.16 |
EPS (TTM) | 1.61 |
Earnings date | 07 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 81.60 |
On May 16, 2024, Renee Tannenbaum, Director at ANI Pharmaceuticals Inc (NASDAQ:ANIP), executed a sale of 2,000 shares of the company.
Eli Lilly's (LLY) two phase III studies on its once-weekly insulin, efsitora alfa, meet their primary endpoint of non-inferior reduction in blood sugar levels compared with daily basal insulins.
Amgen's (AMGN) Imdelltra is the first DLL3-targeting BiTE therapy that activates the patient's own T cells to attack DLL3-expressing tumor cells.